FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.
The prognostic impact of FLT3 mutations on the outcome of patients with diploid AML, treated with intensive chemotherapy, was analyzed. In 176 patients, the frequency of single ITD was 30% (<61 years: 37%, >60 years: 23%), single D835 mutation 2.3%, and both 2.3%. There was no association between ITD and CR rate. ITD-positive patients <61 years had a higher frequency of resistant disease. ITD was adversely associated with CR duration and survival in both younger and elderly patients treated with comparable chemotherapy but the effect was less in the elderly. Presence of both ITD and D835 heralded the least favorable outcome.
Beran
Miloslav
M
Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. mberan@mdanderson.org
Luthra
Rajyalakshmi
R
Kantarjian
Hagop
H
Estey
Elihu
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D004171:Diploidy; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012074:Remission Induction; D015996:Survival Rate; D020080:Tandem Repeat Sequences; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3
D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3